Business Wire

Daiichi Sankyo Europe highlights need to address the perception and classification of CVD risk with data presentations at EAS 2022

Share

Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) announced today multiple data presentations at the European Atherosclerosis Society (EAS) Congress 2022, highlighting the need to address current clinical perceptions and classification of risk of developing or exacerbating cardiovascular disease (CVD).1,2 Latest data from SANTORINI, a multinational, prospective, observational study designed to assess the management of high- and very high-risk CV patients requiring lipid-lowering therapy (LLT) in routine clinical practice, demonstrated that the CV risk of patients analysed was notably underestimated in clinical practice according to European guidelines.1,2,3

Data show that of the 9,044 patients analysed within the SANTORINI study 70.8% of patients were classified by the investigators as being at very high-riskand 29.2% as high-risk of heart attack or stroke. However, of those high-riskpatients, 41.5% demonstrated evidence of atherosclerotic cardiovascular disease (ASCVD) which dictates a very high-riskclassification per the EAS/ESC guidelines. This substantial underestimation of risk highlights a need for more stringent classification of patients against current European guidelines.1,2,3

CV risk assessment is a determining criteria to inform treatment goals for patients with hypercholesteremia.3 Studies have shown a clear, causal effect of LDL-C in the development of ASCVD and, as such, European guidelines recommend use of lipid lowering therapies (LLTs) to reduce overall CV risk in high- and very high-risk patients.3

The 2019 ESC/EAS management of dyslipidaemia guidelines recommend that the LDL-C goals for treating patients at high- and very high-risk of CV events are <1.8 mmol/L and <1.4 mmol/L, respectively.3 Baseline results of the SANTORINI registry presented today show that only 20.1% of patients had achieved their risk-based LDL-C goal, with mean LDL-C levels reported in the clinical setting as 2.41 mmol/L - much higher than European guideline recommendations.1,2 These findings complement data which were presented at the European Society of Cardiology (ESC) Congress in 2021, and further demonstrate the urgent need to reduce LDL-C levels for the 80% of patients that are not currently at target.1,2,4

Despite LDL-C levels being above the recommended values for the majority of patients defined as being at high, or very high-risk of CV events, SANTORINI data show that 54.2% of patients are being treated with monotherapy, and 21.8% reported no use of LLT at all.1,2 European guidelines recommend that the higher a patient’s risk, the more intense therapeutic intervention should be, suggesting that more emphasis needs to be placed on the optimisation of treatment, including combination therapy, for those patients who currently remain at high residual risk of CV events due to their elevated LDL-C.1,2,3

“Today's findings from the SANTORINI study clearly show that as clinicians, we must collectively review and update our perception of risk and associated risk factors when managing cholesterol levels for high- and very high-risk CVD patients. These results underscore a critical discrepancy between guideline recommendations and real-world practice” explained Professor Kausik Ray, Professor of Public Health and President of the European Atherosclerosis Society, Honorary Consultant Cardiologist, Director ICTU Global and Deputy Director of the Imperial Clinical Trials Unit at Imperial College London, and Principal Investigator of SANTORINI. “The vast number of patients who are still not reaching their LDL-C goals, as revealed through the SANTORINI study, highlights that risk classification must be a priority for the clinical community. The EAS/ESCguidelines underscore the need to optimise treatment to achieve LDL-C goals, including making better use of combination therapies, to reduce the risk of atherosclerotic cardiovascular disease and fatalities.”

Dr Garth Virgin, Executive Director Medical Affairs, Specialty Medicines, at Daiichi Sankyo Europe said, “With only 20% of patients reaching their LDL-C goals, it is critical that the pharmaceutical industry continues to support the clinical community to bring the EAS/ESC guidelines into their routine clinical practice and by doing so, help reduce the number of preventable cardiovascular events.” Dr Virgin continues, “there has been substantial progress in the prevention and treatment of cardiovascular disease over recent decades. However, today’s findings from the SANTORINI study highlight the need for greater understanding and collaboration to bring scientific information to the medical community and, ultimately, help to improve patient care.”

-ENDS-

About SANTORINI:

The SANTORINI study is a multinational, prospective, observational study that, to date, has enrolled more than 9,500 patients from over 800 sites in 14 countries across Europe.1 The primary objective is to document, in the real-world setting, the effectiveness of current treatment modalities in managing plasma levels of LDL-C in high- and very high-risk patients requiring lipid-lowering therapies.5 The study population consists of high- and very high-risk patients previously diagnosed and treated as well as newly diagnosed and requiring treatment.5 Initial data on SANTORINI were presented at ESC Congress 2021, organised by the European Society of Cardiology.4

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”

For more information, please visit www.daiichisankyo.com

References


1 Ray KK, et al. Baseline characteristics and management of high- and very high-risk patients with hypercholesterolemia or mixed dyslipidemia in the multinational observational SANTORINI study. Poster presentation at the European Atherosclerosis Society (EAS) Congress 2022. Poster ID 433.
2 Ray KK, et al. Cardiovascular risk assessment by physicians and lipid-lowering therapy prescribing in high- and very high-risk patients: results from the multinational observational SANTORINI study. Poster presentation at the European Atherosclerosis Society (EAS) Congress 2022. Poster ID 1573.
3 The Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidemia. Eur Heart J. 2020 Jan 1;41(1):11–188.
4 Ray KK, et al. Treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe: baseline demographics from the multinational observational SANTORINI study. Presented at European Society Cardiology (ESC) Congress 2021. Poster ID 80441.
5 Clinicaltrials.gov. Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events (SANTORINI). Available at https://clinicaltrials.gov/ct2/show/NCT04271280. Last accessed May 2022.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dr. Wolfgang Schiessl
Daiichi Sankyo Europe GmbH
Director PR and Portfolio Communications, Specialty Medicines
+49 151 1714 7317

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Patients With Allergic Rhinitis2.7.2022 15:08:00 CEST | Press release

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) congress in Prague (Czech Republic), the real-world study confirmed significant benefit of sublingual liquid allergen immunotherapy treatment (AIT) on the onset and worsening of asthma in patients with allergic rhinitis. The retrospective longitudinal pharmaco-epidemiological real-world study included over 430,000 patients: more than 100,000 patients with allergic rhinitis with or without asthma treated with sublingual liquid immunotherapy and symptomatic drugs; compared to more than 330,000 patients with allergic rhinitis with or without asthma treated with symptomatic drugs only. The primary objective of the study was the evaluation of the impact of sublingual liquid AIT on the onset and worsening of asthma in patients with allergic rhinitis. St

Boyd Acquires Sensata’s Thermal Test and Controls Business1.7.2022 17:29:00 CEST | Press release

Boyd, a world-leading innovator of technologies in engineered materials and thermal management, announced it acquired Sensata’s Thermal Test and Controls Business (NYSE:ST). This business specializes in the design and manufacturing of advanced thermal control systems, adapters, and sockets critical to the thermal test process for high-end logic and memory semiconductors. With a long history of serving leading global semiconductor companies, the addition complements Boyd’s existing thermal business, which includes air and liquid cooled thermal management technologies. Boyd designs and manufactures complex thermal solutions for high-performance semiconductors used in applications such as 5G, hyperscale data center, eMobility, and artificial intelligence. With this acquisition, Boyd expands its offering to current semiconductor customers by adding advanced controls and thermal test systems essential to the production of high-end memory and logic devices. “This acquisition is a natural fit

IFF Completed Divestiture of Microbial Control Business1.7.2022 15:45:00 CEST | Press release

IFF (NYSE:IFF) today announced that it has successfully completed the previously announced divestiture of its Microbial Control business unit to LANXESS. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet.Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn. © 2022 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005790/en/Contact information Michael DeVeau Chief Investor Relations

Digi International Unveils Digi XBee LR Module for LoRaWAN Connectivity for IoT Deployments1.7.2022 15:00:00 CEST | Press release

Digi International®, (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) connectivity products, solutions, and services, today unveiled the Digi XBee® LR, the first XBee-class pre-integrated and pre-certified wireless communication module for sensors and end-nodes using LoRaWAN. Coupled with the rich connectivity, device and gateway management capabilities of Digi X-ON™—its Low-Power Wide Area (LPWA) IoT data cloud platform—Digi provides a complete IoT solution with automated provisioning and deployment to help enterprises achieve significant ROI and faster market access. The Digi XBee LR module brings a new connectivity option to one of the most widely adopted wireless IoT module footprints, with more than 20 million devices deployed. This fully developed, tested, and certified module gives OEMs the freedom to create innovative public- or private-cloud solutions for organizations in agriculture, energy, logistics, manufacturing, utilities, and other sectors. These ap

Juniper Networks Announces Cloud Metro Innovation to Drive Sustainable Business Growth for Service Providers1.7.2022 14:35:00 CEST | Press release

Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced the innovation that will power its vision and strategy for Cloud Metro – a new category of solutions for service providers, optimized for metro transformation and sustainable business growth. Traditional “retro” metro networks are device-centric and are buckling under the extreme scale, agility and experience demands that widespread digital transformation and the advent of 5G services are bringing. Today’s announcement focuses on enabling sustainable business growth, with a series of high-performance networking systems, powered by AI-enabled, cloud-delivered automation, specifically designed to build next generation Cloud Metro infrastructure. These systems will deliver significantly-reduced natural resource consumption capabilities to help sustain the planet, improved tools and simplified working methods to help sustain over-pressured operations teams, along with embedded service assurance and secur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom